23/11/2022
EuropaBio hosted its inaugural Healthcare BioForum on October 5, 2022. The roundtable brought together representatives from SMEs, large companies, DGs GROW, Santé and RTD, European Parliament and Member States to discuss links between innovation, investment, and excellence in European healthcare biotechnology.
16/11/2022
European Industry trade and supply chain needs to respond to Covid-19 - Joint Letter to the EU Trade Ministers.
29/06/2021
We, the undersigned CEOs of global biotechnology companies and associations have a social responsibility to work with other stakeholders to ensure that COVID vaccines and treatments get to the patients in the world who most need them.
23/06/2021
Building on the experience of the EU Task Force for Industrial Scale-up of COVID-19 vaccines, the European Commission will facilitate cooperation between actors in the supply […]
07/05/2021
IP waiver for COVID-19 vaccines is a misguided and ineffective response to a shared global challenge
2021_05_H_PR_Waiver of Intellectual Property Rights for COVID-19 Vaccines – EuropaBio’s Position
20/05/2020
Read our latest blog on the impact of the pandemic on patients with chronic diseases and rare conditions around the globe.
30/04/2020
The development of a vaccine or an antiviral treatment is a long and complex process. So why are we hearing that a vaccine against COVID-19 may be ready in a year from now, or even sooner?
30/04/2020
EuropaBio reply letter to EPF's call on COVID-19.
30/04/2020
A recent interview with Prof. Jennifer Doudna, a co-discoverer of the CRISPR-Cas9 system for genome editing, highlights potential applications of the technology to COVID-19.
10/04/2020
European Industry trade and supply chain needs to respond to Covid-19 - Joint Letter to the EU Trade Ministers.
30/03/2020
Learn how biotechnology can contribute towards fighting COVID-19 in our latest blog post.